7 completed, 1 unknown, 1 withdrawn. 9 Phase 3, 3 Phase 2.
By phase and status
Follow pegaptanib: new trials by email Literature Review of pegaptanib trials Research Report on pegaptanib
Trials (filtered) newest first · largest first
All 9 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
A Study of the Safety, Tolerability, and Efficacy of IVT Pre-op 0.3mg Pegaptanib Sodium Versus Sham, for Management of Tractional Retinal Detachment and Vitreous Hemorrhage With Proliferative Diabetic Retinopathy Macugen, Sham - Proliferative Diabetic Retinopathy Phase 3 Withdrawn 2012-04-01 2014-03-05
Study To Evaluate Safety And Tolerability Of Pegaptanib Sodium In Patients With Diabetic Macular Edema pegaptanib sodium - Anti- VGF Inhibitor, Diabetic Macular Edema Phase 3 Completed 46 2011-01-01 2013-09-06
A Phase 3 Study To Compare The Efficacy And Safety Of 0.3 MG Pegaptanib Sodium To Sham Injections In Subjects With Diabetic Macular Edema pegaptanib sodium, sham injection - Macular Edema, Diabetic Mellitus Phase 3 Completed 243 2010-05-01 2013-08-23
Subretinal MacugenĀ® for Neovascular Age-Related Macular Degeneration Pegaptanib (MacugenĀ®) - Age-related Macular Degeneration Phase 3 Unknown 10 2008-11-01 2011-09-27
A Multi-Center Trial To Evaluate The Safety And Efficacy Of Pegaptanib Sodium(Macugen) Injected Into The Eye Every 6 Weeks For Up To 2 Years For Macular Swelling Associated With Diabetes, With An Open-Label Macugen Year Extension. Standard of Care, Macugen - Macular Edema Associated With Diabetes Mellitus Phase 2 / Phase 3 Completed 317 2005-09-01 2018-11-16
A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib Verteporfin photodynamic therapy, Pegaptanib, Triamcinolone acetonide - Macular Degeneration, Choroidal Neovascularization Phase 3 Completed 111 2005-09-01 2016-03-31
Clinical Study Of EYE001 For Wet-Type AMD (Age-Related Macular Degeneration) pegaptanib sodium - Macular Degeneration Phase 3 Completed 90 2004-07-01 2007-05-07
Study of the Safety, Tolerability and Pharmacokinetics of 1 Mg/Eye and 3 Mg/Eye Pegaptanib Sodium in Patients With Exudative Age-Related Macular Degeneration (AMD) pegaptanib sodium (Macugen) - Age-Related Macular Degeneration Phase 2 / Phase 3 Completed 125 2002-11-01 2006-05-03
A Clinical Trial to Explore Safety and Efficacy of Different Doses of Pegaptanib Sodium, Compared to Sham, in Patients With Wet AMD. Pegaptanib sodium - Age-Related Macular Degeneration Phase 2 / Phase 3 Completed 540 2001-05-01 2006-05-04
Conditions studied Macular Degeneration (5) · Choroidal Neovascularization (1) · Diabetic Retinopathy (1) · Macular Edema (1) · Retinal Diseases (1) · Vitreous Hemorrhage (1)
Sponsors Pfizer (4) · Eyetech Pharmaceuticals (2) · Greater Houston Retina Research (1) · Klinikum Ludwigshafen (1) · Novartis Pharmaceuticals (1)
Countries United States (3) · Germany (2) · Japan (2) · United Kingdom (2) · Australia (1) · Austria (1) · Brazil (1) · Canada (1) · Colombia (1) · Czechia (1) · Denmark (1) · Finland (1) · France (1) · Greece (1) · India (1)
Top investigators James C Major, MD (1) · Lars-Olof Hattenbach, MD (1)
Results publications PMID 21896838 , PMID 24997182 , PMID 25187694 , PMID 37260074